Díaz-Dinamarca Diego A, Cárdenas-Cáceres Simone, Muena Nicolás A, Díaz Pablo, Barra Gisselle, Puentes Rodrigo, Escobar Daniel F, Díaz-Samirin Michal, Santis-Alay Natalia T, Canales Cecilia, Díaz Janepsy, García-Escorza Heriberto E, Grifoni Alba, Sette Alessandro, Tischler Nicole D, Vasquez Abel E
Subdepartamento Innovación y Desarrollo, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago 7780050, Chile.
Laboratorio de Virología Molecular, Centro Ciencia & Vida, Fundación Ciencia & Vida, Santiago 8581151, Chile.
Vaccines (Basel). 2024 Aug 15;12(8):919. doi: 10.3390/vaccines12080919.
The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile. Much less is known about the Wuhan-Hu-1 strain-based vaccines in the pediatric population compared to adults. Given the worldwide need for booster vaccinations to stimulate the immune response against new Omicron variants of SARS-CoV-2, we characterized the humoral and cellular immune response against Omicron variant BA.1 in a pediatric cohort aged 10 to 16 years who received heterologous vaccination based on two doses of CoronaVac, two doses of CoronaVac (2x) plus one booster dose of BNT162b2 [CoronaVac(2x) + BNT162b2 (1x)], two doses of CoronaVac plus two booster doses of BNT162b2 [CoronaVac(2x) + BNT162b2 (2x)], and three doses of BNT162b2. We observed that the [CoronaVac(2x) + BNT162b2 (2x)] vaccination showed higher anti-S1 and neutralizing antibody titers and CD4 and CD8 T cell immunity specific to the Omicron variant compared to immunization with two doses of CoronaVac alone. Furthermore, from all groups tested, immunity against Omicron was highest in individuals who received three doses of BNT162b2. We conclude that booster vaccination with BNT162b2, compared to two doses of CoronaVac alone, induces a greater protective immunity.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种及其亚谱系仍在全球范围内导致与新冠病毒疾病（COVID-19）相关的儿科住院、重症和死亡。BNT162b2和科兴疫苗是智利使用的主要疫苗。与成人相比，基于武汉-胡-1毒株的疫苗在儿科人群中的了解要少得多。鉴于全球对加强疫苗接种以刺激针对SARS-CoV-2新奥密克戎变种的免疫反应的需求，我们对10至16岁儿科队列中针对奥密克戎变种BA.1的体液免疫和细胞免疫反应进行了表征，该队列接受了基于两剂科兴疫苗、两剂科兴疫苗（2x）加一剂BNT162b2加强针[科兴疫苗（2x）+BNT162b2（1x）]、两剂科兴疫苗加两剂BNT162b2加强针[科兴疫苗（2x）+BNT162b2（2x）]以及三剂BNT162b2的异源疫苗接种。我们观察到，与仅接种两剂科兴疫苗相比，[科兴疫苗（2x）+BNT162b2（2x）]疫苗接种显示出更高的抗S1和中和抗体滴度以及针对奥密克戎变种的特异性CD4和CD8 T细胞免疫。此外，在所有测试组中，接种三剂BNT162b2的个体对奥密克戎的免疫力最高。我们得出结论，与仅接种两剂科兴疫苗相比，BNT162b2加强疫苗接种可诱导更强的保护性免疫。
